CellaVision ABCVLLY +12.06%69 EV-to-FCF is 24.57 as of Jun. 24, 2026, which is 65% below its 10-year median of 70.66. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 418 Medical Devices & Instruments companies, CellaVision AB ranks worse than 55.02% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CellaVision AB's Enterprise Value is $314.77 Mil.
CellaVision AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $12.81 Mil. Therefore, CellaVision AB's EV-to-FCF for today is 24.57.
The historical rank and industry rank for CellaVision AB's EV-to-FCF or its related term are showing as below:
CVLLY'
s EV-to-FCF Range Over the Past 10 Years
Min: 19.38 Med: 70.66 Max: 832.15
Current: 25.43
During the past 13 years, the highest EV-to-FCF of CellaVision AB was 832.15. The lowest was 19.38. And the median was 70.66.
CVLLY's EV-to-FCF is ranked worse than 55.02% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.66
vs CVLLY: 25.43
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CellaVision AB (OTCPK:CVLLY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CellaVision AB's PE Ratio (TTM) for today is calculated as:
CellaVision AB's share price for today is $7.06.
CellaVision AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.299.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CellaVision AB EV-to-FCF Related Terms
CellaVision AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CellaVision AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CellaVision AB's EV-to-FCF falls into.
CellaVision AB's current Enterprise Value is $314.77 Mil.
CellaVision AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CVLLY) has a EV-to-FCF of 24.57 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CellaVision AB and its competitors. This is 65% below median its historical median of 70.66. Over the past decade, CellaVision AB's EV-to-FCF has ranged from 19.38 to 832.15. According to the industry distribution chart, CellaVision AB ranks #230 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 55%.
Is CellaVision AB's EV-to-FCF too high?
CellaVision AB's current EV-to-FCF of 24.57 is 65% below median its 10-year median of 70.66. Over the past 10 years, this metric has ranged from a low of 19.38 to a high of 832.15. The Medical Devices & Instruments industry median EV-to-FCF is 22.66. CellaVision AB's value of 24.57 is 8.4% above this industry median. Based on the distribution chart, CellaVision AB ranks #230 out of 418 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #230 out of 418 companies for EV-to-FCF. This places CellaVision AB in the lower half of its industry. The industry median EV-to-FCF is 22.66. CellaVision AB's value of 24.57 is 8.4% above this benchmark. Historically, CellaVision AB's own EV-to-FCF has ranged from 19.38 to 832.15 over the past decade. While the company's 10-year median is 70.66 vs. the industry median of 22.66, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.66, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current EV-to-FCF of 24.57 is 8.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current EV-to-FCF is 24.57, which is 65% below median its own 10-year median of 70.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current EV-to-FCF is 24.57, which is 65% below median its 10-year median of 70.66 and 8.4% above the Medical Devices & Instruments industry median of 22.66. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current EV-to-FCF is 24.57 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
EV-to-FCF: 24.57 (65% below median its 10-year median of 70.66)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 8.4% above the Medical Devices & Instruments median (#230 of 418)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
